Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of…
Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed…
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected…
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:…
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms…
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell…
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g.,…
UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor…
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug AdministrationNASH disease education and market development activities expand to…